Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Journal of Medical Virology

Volumn 92, Issue 6, 2020, Pages 568-576

  Wang, Yixuan ^a   Wang, Yuyi ^a   Chen, Yan ^b   Qin, Qingsong ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

COVID 19; diagnosis and interventions; features

Indexed keywords

ALPHA INTERFERON; CHLOROQUINE; GLUCOCORTICOID; LOPINAVIR PLUS RITONAVIR; RIBAVIRIN; ANTIVIRUS AGENT; COVID-19 VACCINE; VIRUS VACCINE;

CHINESE MEDICINE; CLINICAL FEATURE; COMPARATIVE STUDY; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DIET SUPPLEMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL OXYGENATION; GENETICS; HUMAN; INCIDENCE; INCUBATION TIME; INFECTION CONTROL; LABORATORY TEST; MIDDLE EAST RESPIRATORY SYNDROME; MORTALITY RATE; NONHUMAN; OXYGEN THERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS CELL INTERACTION; VIRUS TRANSMISSION; BETACORONAVIRUS; BIOSYNTHESIS; CHINA; COMMUNICABLE DISEASE CONTROL; DRUG EFFECT; LYMPHOCYTOPENIA; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; ORGANIZATION AND MANAGEMENT; PANDEMIC; PASSIVE IMMUNIZATION; PATHOGENICITY; PATHOPHYSIOLOGY; PREVALENCE; PROCEDURES; SARS CORONAVIRUS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; VIROLOGY; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; BETACORONAVIRUS; CHINA; COMMUNICABLE DISEASE CONTROL; CORONAVIRUS INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; LYMPHOPENIA; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; PNEUMONIA, VIRAL; PREVALENCE; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; VIRAL VACCINES;

EID: 85082832833     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.25748     Document Type: Review

References (92)

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579, https://doi.org/10.1038/s41586-020-2012-7
3. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579, https://doi.org/10.1038/s41586-020-2008-3
4. Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. Emerg Microbes Infect. 2020;9(1):313-319.
5. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J. 2020. https://doi.org/10.1097/CM9.0000000000000722
6. Chan JFW, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-523.
7. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. bioRxiv. 2020.
8. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418-423.
9. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-151.
10. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-347.
11. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-574.
12. Li X, Zai J, Zhao Q, et al. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. J Med Virol. 2020. https://doi.org/10.1002/jmv.25731
13. Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260.
14. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. bioRxiv. 2020.
15. Lam TT-Y, Shum MH-H, Zhu H-C, et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. bioRxiv. 2020.
16. Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol. 2020;92:433-440.
17. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001316
18. Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25(4):2000058.
19. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395:689-697.
20. Liu Y, Gayle AA, Wilder-Smith A, Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2), https://doi.org/10.1093/jtm/taaa021
21. Lai A, Bergna A, Acciarri C, Galli M, Zehender G. Early phylogenetic estimate of the effective reproduction number of SARS-CoV-2. J Med Virol. 2020. https://doi.org/10.1002/jmv.25723
22. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020;25(5):2000062.
23. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. https://doi.org/10.1001/jama.2020.1585
24. Respiratory Care Committee of Chinese Thoracic Society. Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;17:E020.
25. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020;26(5), https://doi.org/10.3201/eid2605.200198
26. Bai SL, Wang JY, Zhou YQ, et al. Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54:E005.
27. Rocklov J, Sjodin H, Wilder-Smith A. COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. J Travel Med. 2020. https://doi.org/10.1093/jtm/taaa030
28. Chen H, Guo J, Wang P, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395:809-815.
29. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ. Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. Am J Obstet Gynecol. 2020. https://doi.org/10.1016/j.ajog.2020.02.017
30. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2002032
31. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929-936.
32. Hoehl S, Berger A, Kortenbusch M, et al. Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2001899
33. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12). https://doi.org/10.1056/NEJMc2001737
34. National Health Commission of China. The guidelines for diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (the sixth edition draft) issued by the National Health Commission of China. http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm2020. Accessed February, 2020.
35. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
36. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
37. Fan C, Li K, Ding Y, Lu W, Wang J. ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. medRxiv. 2020.
38. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020.
39. Hui DS, Wong PC, Wang C. SARS: clinical features and diagnosis. Respirology. 2003;8(suppl):S20-S24.
40. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020. https://doi.org/10.1007/s00330-020-06731-x
41. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020. https://doi.org/10.1148/radiol.2020200432
42. Wang M, Wu Q, Xu W, et al. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. medRxiv. 2020. https://doi.org/10.1101/2020.02.12.20022327
43. Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem. 2020. https://doi.org/10.1093/clinchem/hvaa029
44. Xiao SY, Wu Y, Liu H. Evolving status of the 2019 novel coronavirus infection: proposal of conventional serologic assays for disease diagnosis and infection monitoring. J Med Virol. 2020;92(5), https://doi.org/10.1002/jmv.25702
45. Lan L, Xu D, Ye G, et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA. 2020. https://doi.org/10.1001/jama.2020.2783
46. Sun ZF, Meng XJ. Antigenic cross-reactivity between the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus and polyclonal antisera of antigenic group I animal coronaviruses: implication for SARS diagnosis. J Clin Microbiol. 2004;42(5):2351-2352.
47. Zhou G, Chi C. A model simulation study on effects of intervention measures in Wuhan COVID-19 epidemic. med Rxiv. 2020. https://doi.org/10.1101/2020.02.14.20023168
48. Bernard Stoecklin S, Rolland P, Silue Y, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill. 2020;25(6).
49. Notice on the issuance of strategic guidelines for diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (first edition draft).
50. Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79.
51. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-271.
52. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256.
53. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
54. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396), https://doi.org/10.1126/scitranslmed.aal3653
55. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-385.
56. Xia S, Yan L, Xu W, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019;5(4), https://doi.org/10.1126/sciadv.aav4580
57. Li XY, Du B, Wang YS, et al. The keypoints in treatment of the critical coronavirus disease 2019 patient. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E026.
58. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020. https://doi.org/10.1001/jama.2020.2565
59. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antiviral Res. 2017;137:82-92.
60. Chen WH, Du L, Chag SM, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014;10(3):648-658.
61. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22(2), https://doi.org/10.1016/j.micinf.2020.01.003
62. Chen Q, Liang M, Li Y, et al. Mental health care for medical staff in China during the COVID-19 outbreak. Lancet. 2020;7(4), https://doi.org/10.1016/S2215-0366(20)30078-x
63. Chen J. Pathogenicity and transmissibility of 2019-nCoV—a quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2), https://doi.org/10.1016/j.micinf.2020.01.004
64. Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak. Int J Infect Dis. 2020;92:214-217.
65. Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33(4):869-889.
66. Cao C, Chen W, Zheng S, Zhao J, Wang J, Cao W. Analysis of spatiotemporal characteristics of pandemic SARS spread in Mainland China. BioMed Res Int. 2016;2016:7247983.
67. Hui DS. Epidemic and emerging coronaviruses (severe acute respiratory syndrome and Middle East respiratory syndrome). Clin Chest Med. 2017;38(1):71-86.
68. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534.
69. Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via aerosol-generating medical procedures. Viruses. 2019;11(10):940.
70. Sharif-Yakan A, Kanj SS. Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives. PLoS Pathog. 2014;10(12):e1004457.
71. Aevermann BD, Pickett BE, Kumar S, et al. A comprehensive collection of systems biology data characterizing the host response to viral infection. Sci Data. 2014;1:140033.
72. Malik YS, Sircar S, Bhat S, et al. Emerging novel coronavirus (2019-nCoV)—current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40:68-76.
73. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020.
74. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-1325.
75. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125(4):1011-1017.
76. GENG QS. Guidelines for the prevention and treatment of SARS. Dongguan Sci Technol J. 2003;5:7.
77. Chau TN, Lee KC, Yao H, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004;39(2):302-310.
78. Du HWQ, Ma Y. Analysis of SARS inpatients in Beijing in 2003. Chin Gen Pract 2004;7(4):231-232.
79. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752-761.
80. Hijawi B, Abdallat M, Sayaydeh A, et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J. 2013;19(suppl 1):S12-S18.
81. Assiri AM, Mcgeer A, Perl TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369:407-416.
82. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-COV) in humans. PLoS Curr. 2013;5.
83. Guery B, Poissy J, el Mansouf L, et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet. 2013;381(9885):2265-2272.
84. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368(26):2487-2494.
85. National Health and Family Planning Commission of People's Republicao of China. Diagnosis and treatment plan for Middle East respiratory syndrome cases (2015 edition). Virologica Sinica. 2015;(5):352354.
86. Lee JY, Kim YJ, Chung EH, et al. The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015. BMC Infect Dis. 2017;17(1):498.
87. World Health Organization. WHO MERS global summary and assessment of risk. https://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf. Accessed July, 2019.
88. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ. 2003;326(7403):1358-1362.
89. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820.
90. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 2013;13(9):745-751.
91. Dyall J, Gross R, Kindrachuk J, et al. Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. Drugs. 2017;77(18):1935-1966.
92. Chan PK, Tang JW, Hui DS. SARS: clinical presentation, transmission, pathogenesis and treatment options. Clin Sci. 2006;110(2):193-204.